Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis.

Supriya R KulkarniCarol J SorokaLee R HageyJames L Boyer

Published in: Hepatology (Baltimore, Md.) (2016)

SRT1720 administration alleviates cholestatic liver injury in mice by increasing hydrophilicity of hepatic BA composition and decreasing plasma BA concentration through increased BA excretion into urine. Thus, use of small-molecule activators of Sirt1 presents a novel therapeutic target for cholestatic liver injury. (Hepatology 2016;64:2151-2164).

Keyphrases

liver injury
drug induced
mouse model
small molecule
oxidative stress
protein protein
ischemia reperfusion injury